Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ionis: Another Shot At The Commercial Market And Sustainable Profits

Executive Summary

Spinraza, launched by partner Biogen, is the antisense developer’s newest drug to reach the market. Ionis plans to file its first wholly-owned drug, volanesorsen, later this year.

Advertisement

Related Content

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line
Finance Watch: Raising Cash Before A Trump Slump, La Jolla Nabs $125m, Akcea Eyes $100m IPO
Akcea Faces Tricky Risk/Benefit Scenario In Orphan Disease FCS
Biogen Forecasts Gradual Launch For Life-Transforming Drug Spinraza
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
Novartis Spreads Cardiovascular Bets with Ionis Antisense Option Deal
Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016
Ionis Subsidiary Akcea Encouraged By Safety Data In FCS
Ionis Sells Kynamro To Kastle After Regaining Rights From Genzyme

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel